Table. 3. Table 3

Outcomes of the subgroup analyses of parameters

Subgroup	No. of trials (no. of participants)	Effect size (95% CI)	P-value	I2 (%)	P heterogeneity	P for between subgroup heterogeneity
CRP
Mean age (year)						<0.0001
≤50	8 (384)	0.47 (—0.18, 1.11)	0.1550	93.06	<0.0001
>50	4 (247)	0.01 (—0.43, 0.45)	0.9534	37.72	0.1857
Study design						<0.0001
Parallel	11 (581)	0.44 (—0.19, 1.1)	0.1677	89.47	<0.0001
Crossover	2 (80)	—0.001 (—0.05, 0.05)	0.9667	0	0.4075
Dose (mg/d)						<0.0001
≤300	4 (177)	0.86 (—0.50, 2.24)	0.2147	89.70	<0.0001
>300	9 (471)	0.07 (—0.46, 0.60)	0.7864	89.58	<0.0001
Duration (week)						<0.0001
≤8	9 (370)	0.50 (0.08, 0.92)	0.0188	81.06	<0.0001
>8	4 (291)	—0.26 (—1.25, 0.73)	0.6068	85.26	0.0001
Sex						<0.0001
Female	3 (143)	0.39 (—0.36, 1.13)	0.3132	59.31	0.0856
Both	10 (505)	0.28 (—0.35, 0.90)	0.3896	89.57	<0.0001
Type of supplementation						<0.0001
Epigallocatechin	3 (152)	0.21 (—0.63, 1.05)	0.6230	64.11	0.0617
Tea	4 (196)	0.95 (—0.41, 2.32)	0.1691	82.61	0.0006
Extract	6 (313)	0.01 (—0.64, 0.66)	0.9797	93.10	<0.0001
IL-6
Mean age (year)						<0.0001
≤50	4 (125)	—0.76 (—2.12, 0.59)	0.2724	86.27	<0.0001
>50	1 (44)	—0.44 (—1.16, 0.28)	0.2343	0	1
Study design						0.2374
Parallel	4 (136)	—0.19 (—0.68, 0.30)	0.4533	29.13	0.2374
Crossover	1 (20)	—4.0 (—5.71, —2.28)	<0.0001	0	1
Dose (mg/d)						<0.0001
≤300	2 (69)	—0.27 (—0.80, 0.27)	0.3223	0	0.4947
>300	3 (87)	—1.10 (—3.29, 1.08)	0.3218	90.34	<0.0001
Sex						0.0008
Female	2 (65)	—2.16 (—5.58, 1.25)	0.2143	92.61	0.0002
Both	3 (91)	—0.02 (—0.67, 0.63)	0.9469	39.63	0.1908
Type of supplementation						<0.0001
Epigallocatechin	1 (44)	—0.44 (—1.16, 0.28)	0.2343	0	1
Tea	2 (70)	—0.31 (—0.83, 0.22)	0.2487	0	0.4129
Extract	2 (42)	—1.52 (—6.30, 3.27)	0.5349	95.13	<0.0001

Prev Nutr Food Sci 2024;29:106~117 https://doi.org/10.3746/pnf.2024.29.2.106